

specific antibodies as part of an ex vivo method for transplanting cells. The claimed invention is therefore not obvious over Blazar in light of Chappel.

Applicants respectfully request withdrawal of the rejection of claims 1-10 under 35 U.S.C. §103.

CONCLUSION

In view of the foregoing remarks, Applicants respectfully request the reconsideration and reexamination of this application and the timely allowance of the pending claims.

Please grant any extensions of time required to enter this filing and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 5, 2003

By: E. Stewart Mittler
E. Stewart Mittler
Reg. No. 50,316

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com